Clinical Trials

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07520760 2026-04-09

MBC-EA

52 enrolled

Breast Neoplasms

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

30 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07494448 2026-03-27

JAZMINE

24 enrolled

Breast Neoplasms

NCT07173751 2026-03-25

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

558 enrolled

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast Neoplasms

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

184 enrolled

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT05810870 2026-03-10

SABINA

14 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

400 enrolled

Breast Neoplasms, Recurrence

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

644 enrolled

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT07088263 2025-12-11

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

192 enrolled

Breast Neoplasms

NCT06081959 2025-12-05

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

376 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07255612 2025-12-01

Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)

29 enrolled

Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03264547 2025-09-29

EMERALD

Phase 3 Completed

446 enrolled

Breast Neoplasms

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

226 enrolled

Breast Neoplasms

NCT05063786 2025-09-08

ALPHABET

27 enrolled

Breast Neoplasms

NCT06383767 2025-06-19

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

378 enrolled

Breast Neoplasms

NCT02061085 2025-06-08

MERIBEL

Phase 2 Completed

53 enrolled 11 charts

Breast Neoplasms, Ketosis, Neoplasm Metastasis

NCT03222856 2025-06-05

KELLY

Phase 2 Completed

44 enrolled 17 charts